Tweet
Genetic Engineering News
<img alt="" height="1" width="1" />
Arena Release Results of BLOOM-DM Trial on Lorcaserin
eMaxHealth
Arena Pharmaceuticals Inc released data from it's Phase III BLOOM-DM trial earlier this week on lorcaserin hydrochloride, a weight-loss drug, which was rejected by the Food and Drug Administration (FDA) last month. The FDA expects obesity drugs to show ...
Arena, Eisai Obesity Drug Shows Success In Diabetes PatientsWall Street Journal
Arena weight-loss drug caused heart troubleSan Francisco Chronicle
Arena Diet Medicine Increases Heart Risk for Obese Diabetics in PatientsBloomberg
Pharmaceutical Business Review -FierceBiotech -HealthNews
all 95 news articles »
More...